Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
28 févr. 2022 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
04 févr. 2022 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences to Host Virtual Investor Event
01 déc. 2021 08h00 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new...
Imago BioSciences to Present at Stifel 2021 Virtual Healthcare Conference
11 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
10 nov. 2021 16h05 HE
|
Imago Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the...
Imago BioSciences to Present First Clinical Data for IMG-7289 At 24th Congress of the European Hematology Association
21 mai 2019 11h27 HE
|
Imago BioSciences, Inc.
San Francisco, CA, May 21, 2019 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an...